Citius Oncology, Inc. Increase (Decrease) in Accounts Payable, Trade
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Accounts Payable, Trade of -$5.92 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-14
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$1.57M, a 258.18% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was -$1.56M, a 186.79% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$2.79M, a 228.89% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $4.57M, a 23.05% increase year-over-year.
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for fiscal 2025 was $9.52M, a 293.10% increase from fiscal 2024.
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was $2.42M, a 102.43% increase from fiscal 2023.
- Citius Oncology, Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was $1.20M.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$3.13M derived: sum of 2 quarters · filed 2026-08-14 | -$5.92M 10-Q · filed 2026-08-14 | -$1.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | -$4.35M 10-Q · filed 2026-05-15 | $215.82K derived: sum of 3 quarters · filed 2026-05-15 | $1.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$2.79M 10-Q · filed 2026-02-13 | $1.78M derived: sum of 2 quarters · filed 2026-02-13 | $2.77M derived: sum of 3 quarters · filed 2026-08-14 | $4.57M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $5.56M derived: sum of 2 quarters · filed 2026-08-14 | $7.36M derived: sum of 3 quarters · filed 2026-08-14 | $9.52M 10-K · filed 2025-12-23 |
| 2025-06-30 | $991.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $2.79M derived: sum of 2 quarters · filed 2026-08-14 | $4.96M 10-Q · filed 2026-08-14 | $8.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $3.96M 10-Q · filed 2026-05-15 | $7.68M derived: sum of 3 quarters · filed 2026-05-15 | $7.17M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.16M 10-Q · filed 2026-02-13 | $5.87M derived: sum of 2 quarters · filed 2026-02-13 | $5.37M derived: sum of 3 quarters · filed 2026-02-13 | $5.67M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $3.21M derived: sum of 2 quarters · filed 2025-12-23 | $3.51M derived: sum of 3 quarters · filed 2025-12-23 | $2.42M 10-K · filed 2025-12-23 |
| 2024-06-30 | -$503.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | -$205.02K derived: sum of 2 quarters · filed 2025-08-12 | -$1.29M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $298.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | -$785.13K 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | -$1.08M 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | $1.20M 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |